1
|
Mohammed S, Costantino SC, Akhmedov AA, Karsay GK, Ambrosini SA, Madeddu PM, Gaia GS, Luscher TF, Paneni FP. Pharmacological blockade of histone methyltransferase SETD7 restores angiogenic response in experimental diabetes. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Peripheral artery disease (PAD) is highly prevalent in patients with diabetes and associates with a high rate of limb amputation and poor prognosis. Surgical and catheter-based revascularization have failed to improve outcome in diabetic patients with PAD. Hence, a need exists to develop new treatment strategies able to promote blood vessel growth in the ischemic limb of diabetic patients. Mono-methylation of histone 3 at lysine 4 (H3K4me1) - a specific epigenetic signature induced by the methyltransferase SETD7 - favours a chromatin active and open state thus enabling the gene transcription.
Purpose
To investigate whether SETD7-dependent epigenetic changes modulate post-ischemic vascularization in experimental diabetes.
Methodology
Primary human aortic endothelial cells (HAECs) were exposed to normal glucose (NG, 5 mM) or high glucose (HG, 20 mM) concentrations for 48 hours. Unbiased gene expression profiling was performed by RNA sequencing (RNA-seq) followed by Ingenuity Pathway Analysis (IPA). In vitro angiogenic assays like migration assay & tube formation assay were performed. Pharmacological blockade of SETD7 was achieved by using the highly selective inhibitor called (R)-PFI-2. T1D mice (streptozotocin-induced diabetes) was orally treated with (R)-PFI-2 and with vehicle for 21 days and followed by induction of hindlimb ischemia. Blood flow recovery was analyzed at 30 minutes, 7 and 14 days by laser doppler imaging. Gastrocnemius muscle samples from patients with and without T2D were employed to translate our experimental findings.
Results
RNA-seq in HG-treated HAECs revealed a profound upregulation of the methyltransferase SETD7, an enzyme involved in mono-methylation of lysine 4 at histone 3 (H3K4me1). SETD7 upregulation in HG-treated HAECs was associated with an increase of H3K4-mono-methylation levels as well as with impaired endothelial cell migration and tube formation. Of interest, both gene silencing (SETD7-siRNA) and pharmacological blockade of SETD7 by (R)-PFI-2 rescued hyperglycemia-induced impairment of angiogenic properties in HAECs. RNA-seq in HG-treated HAECs with and without SETD7 depletion unveiled an array of differentially expressed genes, which were mainly involved in blood vessel growth and angiogenic response. Among dysregulated genes, Chromatin immunoprecipitation (ChIP) assays showed that SETD7 specifically mono-methylates H3K4m1 in proximity of Semaphorin-3G (SEMA3G) promoter, thus regulating its expression. Treatment of T1D mice with (R)-PFI-2 improved blood flow reperfusion at 14 days as compared to vehicle-treated animals. Finally, SETD7/SEMA3G axis was upregulated in muscle specimens from T2D patients.
Conclusion
Targeting SETD7 represents a novel epigenetic-based therapy to boost neovascularization in diabetic patients with PAD.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): University of Zurich
Collapse
Affiliation(s)
- S Mohammed
- University of Zurich, Zurich, Switzerland
| | | | | | - G K Karsay
- Universitätsspital Zürich, Institute for Clinical Chemistry, Zürich (Zürich), Switzerland
| | | | - P M Madeddu
- University of Bristol, Bristol Royal Infirmary, London, United Kingdom
| | - G S Gaia
- Cardiology Center Monzino IRCCS, Cardiovascular research unit, Milan, Italy
| | - T F Luscher
- Royal Brompton and Harefield Hospital, London, United Kingdom
| | - F P Paneni
- University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Mohammed S, Mattia MA, Gergely GK, Gaia GS, Ambrosini SA, Paolo PM, Thomas F TFL, Sarah SC, Gian Paolo GPF, Francesco FP. The BET protein inhibitor apabetalone (RVX-208) restores angiogenic response in type 1 and type 2 diabetes by transcriptional regulation of thrombospondin-1. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Peripheral artery disease (PAD) is highly prevalent in people with type 2 diabetes and associates with chronic limb ischemia and poor prognosis. Understanding the mechanisms of impaired blood vessel growth in diabetic patients is of paramount importance to develop new angiogenic therapies in this setting. Dysregulation of epigenetic mechanisms of gene transcription in vascular cells contributes to cardiovascular disease development but is currently not targeted by therapies. Apabetalone (RVX-208) – an FDA approved small molecule inhibitor of the epigenetic readers bromodomain and extra-terminal (BET) proteins – has recently shown to modulate transcriptional programs implicated in vascular inflammation and atherosclerosis.
Purpose
To investigate RVX-208 effects in modulating angiogenic response and post-ischemic vascularization in diabetes.
Methods
Primary human aortic endothelial cells (HAECs) were exposed to normal glucose (NG, 5 mM) or high glucose (HG, 20 mM) for 48 hours in presence of RVX-208 (20μM) or vehicle (DMSO). Scratch and tube formation assays were performed to investigate the impact of RVX-208 on angiogenic properties of HAECs. T1D mice (streptozotocin-induced diabetes) and T2D mice (Lepdb/db) were orally treated with apabetalone or vehicle for 5 days. Hindlimb ischemia was induced in T1D mice & blood flow recovery analysed at 30 minutes, 7 and 14 days by laser Doppler imaging. Sprouting and matrigel plug assays were performed in Lepdb/db mice. Gastrocnemius muscle samples from patients with and without T2D were employed to translate our experimental findings.
Results
HG impaired HAECs migration and tube formation as compared to NG, whereas treatment with RVX-208 rescued HG-induced impairment of angiogenic properties. Real time PCR arrays in HG-treated HAECs showed that RVX-208 treatment prevents the dysregulation of genes implicated in endothelial migration, sprouting and inflammation, namely the anti-angiogenic molecule thrombospondin (THBS1), VEGF-A, IL-1β, IL-6, VCAM-1, and CXCL1. Of interest, both gene silencing of BET protein (BRD4) or its pharmacological inhibition by RVX-208 reduced THBS1 expression while restoring VEGFA levels in HG-treated HAECs. ChIP assays showed the enrichment of both BRD4 and the active chromatin mark H3K27Ac on THBS1 promoter. Mechanistic experiments uncovered the inhibitory role of THBS1 on VEGFA signalling, as also confirmed by STRING analysis. Treatment of T1D mice with RVX-208 improved blood flow reperfusion and vascular density at 14 days as compared to vehicle-treated animals. Moreover, RVX-208 restored endothelial sprouting in T2D-Lepdb/db mice. Of clinical relevance, THBS1 was upregulated while VEGFA expression was reduced in gastrocnemius muscle specimens from T2D patients with PAD as compared to non-diabetic controls.
Conclusion
In vivo targeting of BET-proteins by RVX-208 may represents a novel therapeutic approach to boost post-ischemic neovascularization in diabetes.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): University of Zurich
Collapse
Affiliation(s)
- S Mohammed
- University of Zurich, Centre for Molecular Cardiology, Zurich, Switzerland
| | - M A Mattia
- University of Padua, Veneto Institute of Molecular Medicine, Padova, Italy
| | - G K Gergely
- University Hospital Zurich, Clinical Chemistry, Zurich, Switzerland
| | - G S Gaia
- Cardiology Center Monzino IRCCS, Cardiovascular Research Unit, Milan, Italy
| | - S A Ambrosini
- University of Zurich, Centre for Molecular Cardiology, Zurich, Switzerland
| | - P M Paolo
- University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
| | - T F L Thomas F
- Royal Brompton and Harefield Hospital, London, United Kingdom
| | - S C Sarah
- University of Zurich, Centre for Molecular Cardiology, Zurich, Switzerland
| | - G P F Gian Paolo
- University of Padua, Veneto Institute of Molecular Medicine, Padova, Italy
| | - F P Francesco
- University Hospital Zurich, Centre for Molecular Cardiology, Zurich, Switzerland
| |
Collapse
|